OrbiMed’s Ocular Therapeutix OCUL Stock Holding History

OrbiMed’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.16M	Buy	+220,000	New	+$1.99M	0.04%	121
2026 Q1	–	Sell	-157,300	Closed	-$1.91M	–	123
2025 Q4	$1.91M	Buy	+157,300	New	+$1.91M	0.04%	101
2016 Q1	–	Sell	-155,000	Closed	-$1.45M	–	144
2015 Q4	$1.45M	Sell	155,000 -53,900	-26%	-$582K	0.01%	119
2015 Q3	$2.94M	Buy	+208,900	New	+$4.2M	0.03%	121

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed's OCUL Position: Q2 2026 in Review

OrbiMed opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 220,000 shares worth $2.16M. The stake represents 0.04% of the portfolio and ranks #121 among its holdings. This is a return to the name: OrbiMed previously reported a position in OCUL as recently as Q4 2025.

OrbiMed first reported a position in OCUL in Q3 2015 and has held it in 4 quarters since. The position peaked at $2.94M in Q3 2015. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

OrbiMed held 220,000 shares of Ocular Therapeutix worth $2.16M as of Q2 2026.
Ocular Therapeutix was a new OrbiMed position in Q2 2026.
Ocular Therapeutix made up 0.04% of OrbiMed's portfolio in Q2 2026, its #121 holding.
OrbiMed first reported a position in Ocular Therapeutix in Q3 2015 and has held it in 4 quarters since.
OrbiMed's Ocular Therapeutix position peaked at $2.94M in Q3 2015.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.